Will Immunotherapy Shift the Balance of Treatment for Borderline Resectable Stage III NSCLC Away from Surgery? (BMIC-014)
Dr. Jack West reviews the implications of the PACIFIC trial that establishes a role for durvalumab immunotherapy in stage III NSCLC, and which will likely lead to some patients shifting away from surgery in favor of chemoradiation followed by durvalumab. (7:01)